ストックスクリーナーアプリを入手
28.90
3.92%
-1.18
アフターアワーズ：
28.86
-0.04
-0.14%
Beam Therapeutics Inc (BEAM) 最新ニュース
Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake Disclosure - Yahoo Finance
Prime Editing and CRISPR Market is expected to Hit US$ 11.46 - openPR.com
Beam Therapeutics’ TIME Honor Puts Base Editing And Valuation In Focus - Yahoo Finance
Beam Therapeutics Advances Base Editing Platform with Strong Clinical Data - HarianBasis.co
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now? - Insider Monkey
14 Stocks on Jim Cramer’s Radar: Nokia, Cameco, and AI Stocks’ Dip - Insider Monkey
Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation” - Insider Monkey
Price-Driven Insight from (BEAM) for Rule-Based Strategy - Stock Traders Daily
MSN Money - MSN
Vanguard Capital Mgmt (NASDAQ: BEAM) reports 5.02% ownership stake - Stock Titan
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Insider Monkey
Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM - MarketBeat
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Beam Therapeutics (BEAM) Projected to Post Earnings on Tuesday - MarketBeat
Beam Therapeutics shows rising relative strength; still shy of key benchmark - MSN
Beam Therapeutics (NASDAQ:BEAM) Trading Up 8.4%What's Next? - MarketBeat
Beam Therapeutics (BEAM) Shares Surge 10.7% on Positive Market M - GuruFocus
S&P 500 Holds Near Highs Despite Oil Shock and Weak Breadth Data - Investing.com
Beam Therapeutics (BEAM) Shares Rise Over 10% Amid Positive Mark - GuruFocus
XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
3 Biotech Stocks That Could Benefit from the Patent Cliff - MarketBeat
Beam Therapeutics (BEAM) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr
Beam Therapeutics (BEAM) Q4 2025 earnings summary - Quartr
Beam Therapeutics (BEAM) Q3 2024 earnings summary - Quartr
Beam Therapeutics (BEAM) Status Update Summary - Quartr
Beam Therapeutics (BEAM) Jefferies 2024 Global Healthcare Conference Summary - Quartr
Beam Therapeutics (BEAM) Jefferies London Healthcare Conference 2024 Summary - Quartr
Beam Therapeutics Inc. (BEAM) reports Q4 loss, beats revenue estimates - MSN
Stocks flashing renewed technical strength: Beam Therapeutics - MSN
Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.7%What's Next? - MarketBeat
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN
Gene Editing Tools Market is expected to Hit US$ 1,700.05 Million - openPR.com
BEAM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BEAM Price Today: Beam Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
This Beam Therapeutics Insider Reduced Their Stake By 42% - 富途牛牛
(BEAM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Executive pay and board elections at Beam Therapeutics (NASDAQ: BEAM) 2026 virtual meeting - Stock Titan
[ARS] Beam Therapeutics Inc. SEC Filing - Stock Titan
Beam Therapeutics (BEAM) Is Up 20.6% After Positive Gene-Editing Data And New Credit FacilityHas The Bull Case Changed? - Yahoo Finance
BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
[144] Beam Therapeutics Inc. SEC Filing - Stock Titan
Sumitomo Mitsui Trust Group Inc. Has $122.23 Million Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Baillie Gifford & Co. Boosts Beam Therapeutics Stake by 40% - National Today
Baillie Gifford & Co. Acquires 118,421 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Trading Up 9.1%Here's What Happened - MarketBeat
Beam Therapeutics CEO Sells 30,078 Shares in April 2026 Transaction | Stock UpdateNews and Statistics - IndexBox
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. - Yahoo Finance
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $47 - Moomoo
Beam Therapeutics President Sells $290,289 in Stock - National Today
(BEAM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Beam Therapeutics CEO Sells Over $700K in Stock - National Today
BEAM Forecast, Price Target & Analyst Ratings | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics Insider Sells $146K in Shares - National Today
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Beam Therapeutics CEO Evans sells $739k in stock By Investing.com - Investing.com Australia
Amy Simon, Beam Therapeutics CMO, sells $164,686 in stock By Investing.com - Investing.com India
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):